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We have examined whether parental exposure to atomic bomb radiation has led to increased cancer risks among the offspring. We
studied 40487 subjects born from May 1946 through December 1984 who were cancer-free in January 1958. One or both parents
were in Hiroshima or Nagasaki at the time of the bombing and for childbirth. Using population-based tumor registry data we analyzed
cancer incidence data from 1958 to 1997 by Cox regression models, and we examined the effects of both paternal and maternal
irradiation with adjustment for city, sex, birth year, and migration. During follow-up, 575 solid tumor cases and 68 hematopoietic
tumor cases were diagnosed. Median age at diagnosis was 39.7 years. Median doses were 143 millisierverts for 15992 exposed (5þ
millisierverts or unknown dose) fathers and 133 millisierverts for 10066 exposed mothers. Cancer incidence was no higher for
subjects with exposed parents than for the reference subjects (0–4 millisierverts), nor did the incidence rates increase with increasing
dose. For 3568 subjects with two exposed parents, the adjusted risk ratio for all cancer was 0.97 (95% confidence interval 0.70–
1.36). Because of the small number of cases, however, we cannot exclude an increase in cancer incidence at this time.
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Our long-term study of a large cohort of offspring of atomic-bomb
survivors screens regularly for possible effects of parental
preconception exposure to radiation. The latest mortality study
(Izumi et al, 2003) suggested that such exposure did not lead to
increased cancer mortality rates in childhood and young adult-
hood among the offspring born in Hiroshima and Nagasaki. This
finding is consistent with earlier studies of the cohort, which found
no dose-dependent increases in mortality (Kato et al, 1966; Neel
et al, 1974; Yoshimoto et al, 1991; Little et al, 1994), childhood
cancer (Yoshimoto et al, 1990), untoward pregnancy outcomes
(Neel and Schull, 1956; Otake et al, 1990), cytogenetic abnormal-
ities (Awa et al, 1987), or loss of enzyme activity (Neel et al, 1988).
However, because cancers with high survival rates could not be
adequately evaluated by mortality data, the effects of parental
irradiation on cancer risks among the offspring need to be
examined using the cancer incidence data.
In the present cohort study, we used population-based tumor
registry data to examine whether parental exposure to atomic
bomb radiation was associated with higher cancer incidence rates
among the offspring born in Hiroshima and Nagasaki. We
examined the effects of paternal and maternal irradiation on
cancer risks among offspring both before and after they were 20
years of age.
METHODS
Study population
We analyzed a subset of the F1 mortality study cohort of the
Radiation Effects Research Foundation (RERF), Japan (Kato and
Schull, 1960; Yoshimoto et al, 1990), consisting of 40487 Japanese
offspring (20743 men and 19744 women) born from 1 May 1946
through 31 December 1984. They were conceived between 1 month
and 38 years after the atomic bombing in August 1945 and one or
both parents were in either city of Hiroshima or Nagasaki at the
time of the bombing and for the childbirth. Almost two-thirds were
born in Hiroshima, the majority between 1946 and 1959. Radiation
dose was known for at least one parent. The subjects were alive and
cancer-free in January 1958. Family and biological relationships
were established from birth records, parental interviews, and
maternal pregnancy data (Neel and Schull, 1956). The study
sample did not include persons born to atomic-bomb survivors
who had moved away from the cities after the bombings.
Follow-up/identification of cancer cases
We assessed cancer incidence from 1 January 1958 through 31
December 1997 through population-based tumor registries in
Hiroshima and Nagasaki. These registries have collected informa-
tion from local hospitals and death certificates since 1957 for
Hiroshima and 1958 for Nagasaki. Tissue registries have been
providing supplemental information about tumor cases to the
tumor registries. Neither a nation-wide tumor registry nor access
to other tumor registries has been established. Details of the
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ymethodology have been published elsewhere (Mabuchi et al, 1994).
The RERF Human Investigation Committee approved the research
protocol for the F1 epidemiologic studies. Residency information
for each cohort member was in-accessible because of privacy laws,
so residence probabilities in the tumor registry catchment areas
were used instead to adjust for the possible effects of migration on
cancer risks (Sposto et al, 1992).
We classified the end points into two groups based on the
International Classification of Diseases, 9th Revision (ICD-9)
(World Health Organization, 1977): (1) hematopoietic tumors,
including leukemia (ICD-9 204–208), Hodgkin’s and non-Hodg-
kin’s lymphoma (ICD-9 200–202), and multiple myeloma (ICD-9
203) and (2) other malignant (solid) tumors (ICD-9 140–199)
together with benign brain and central nervous system tumors
(ICD-9 225). We recorded final case status (cancer or cancer-free),
age at which the individual ceased to contribute person-years of
follow-up (age at diagnosis of first primary cancer, death, or the
end of follow-up, whichever occurred first), and age at entry to the
study.
Parental data
Parental data included date of birth and gonadal dose as estimated
by the DS86 dosimetry system (Roesch, 1987; National Academy of
Science, 1990). Mean age at the time of bombing was 24.4 years
(standard deviation 9.2) for fathers and 19.8 years (standard
deviation 7.7) for mothers. As in recent mortality studies of
atomic-bomb survivors (Pierce et al, 1996; Shimizu et al, 1999), we
adjusted for dose error and used a weighted dose (the gamma dose
plus 10 times the neutron dose). In contrast to certain previous
studies of childhood cancer, this study examined paternal and
maternal doses separately rather than combining them into a
conjoint dose.
We divided parental doses into seven groups: 0–4 millisierverts
(mSv) (reference group), 5–49, 50–149, 150–499, 500–4000,
unknown dose (exposed, but with insufficient information on
dose), and not in city at the time of the bombing. Doses above
4mSv were divided into quartiles. We defined exposed parents as
those with doses exceeding 4mSv or with unknown dose. Dose
measured in units of 100mSv were used to test for a linear dose-
response.
As shown in Table 1, 22490 (56%) had one or two exposed (5þ
mSv or unknown dose) parents, while 3568 (8.8%) had two
exposed parents. Median doses were 143mSv for 15992 exposed
fathers (range 5–3835) and 133mSv for 10066 exposed mothers
(range 5–3103). The association between paternal and maternal
doses was low (correlation coefficient 0.02 for the subjects whose
parents were both in city with known dose).
Statistical methods
We analyzed cancer incidence rates for subjects both before and
after they were 20 years of age. We used Cox regression models to
compute risk ratios and 95% confidence intervals for paternal and
maternal radiation dose (using either groups or continuous values)
with adjustment for the baseline rates for city, sex, year of birth,
age at entry, and residency. Residence probabilities were estimated
by city (Hiroshima, Nagasaki), sex (male, female), and calendar
period (1958–60, 61–65, 66–70, 71–75, 76–80, 81–85, 86–90,
91–97). We also checked proportionality of hazard rates
(Therneau and Grambsh, 2000). We found in a preliminary
analysis that the results from Poisson regression models were
similar to those from Cox regression models. Heterogeneity of risk
ratios was tested among the groups of subjects whose parents were
in either city of Hiroshima or Nagasaki at the time of the bombing.
Evidence of any linear dose-response was also investigated among
the subjects whose parents were in either city at the time of the
bombing with known dose. We calculated two-sided P values, with
values less than 0.05 indicating significance. EPICURE software
was used for all statistical analyses (Preston et al, 1993).
RESULTS
During the 40-year period of follow-up (Table 2), 575 cases of solid
tumors and 68 cases of hematopoietic tumors were diagnosed,
representing a 1.4 and 0.2% cumulative incidence, respectively. Of
these, 551 solid tumor and 44 hematopoietic tumor cases were
diagnosed above age 20 years. For 3568 subjects with two exposed
parents, 55 and 6 developed solid and hematopietic tumors,
respectively. Age at onset ranged from 0.8 to 50.9 years with a
median of 39.7, and attained age for cancer-free subjects ranged
from 0.003 to 51.7 years with a median of 44.9. Mean length of
follow-up was 39.3 years. As subjects aged, the number of solid
tumors increased far more than that of hematopoietic tumors,
particularly in the digestive system. Other major tumor sites were
breast, genital organ, and thyroid for female subjects and
respiratory system, prostate, and urinary system for male subjects.
In the course of follow-up, 77% of the subjects had passed their
40th year.
Cancer incidence rates were no higher among the subjects with
one or two parents exposed than among the reference subjects
(Tables 3 and 4). For the subjects with two exposed parents, the
adjusted risk ratio was 0.97 (95% Confidence Interval (CI) 0.70–
1.34) for all cancers, 0.97 (95% CI 0.69–1.36) for solid tumors, and
0.95 (95% CI 0.32–2.64) for hematopoietic tumors. Cancer
incidence rates were not positively associated with either paternal
or maternal radiation exposure (P40.1). Regarding a possible
Table 1 Distribution of parental radiation dose among 40487 offspring of atomic-bomb survivors and controls
Paternal dose
mSv (mean) 0–4
a 5–49 50–149 150–499 500–4000 Unknown Not in city Total
Maternal dose (0) (22) (91) (290) (1148) (–) (0)
0–4
a (0) 5322 758 511 570 430 524 3279 11394
5–49 (22) 532 435 206 128 60 148 564 2073
50–149 (92) 476 174 285 90 45 111 667 1848
150–499 (291) 515 169 113 272 55 89 601 1814
500–4000 (1004) 628 121 58 105 158 103 739 1912
Unknown (–) 931 216 136 169 122 0 845 2419
Not in city (0) 9396 1597 1901 1974 1711 2448 0 19027
Total 17800 3470 3210 3308 2581 3423 6695 40487
aClassified as the reference group.
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100mSv was 0.96 (95% CI 0.92–1.00) for paternal exposure and
1.01 (95% CI 0.98–1.04) for maternal exposure. No trend toward
increasing cancer incidence was found for increasing dose
(P40.05), but a decreasing incidence with increasing paternal
dose was suggested (P¼0.08). The adjusted risk did not change
with age, calendar period, sex, or parental age at the time of the
bombing (P40.1). Findings were similar whether cancer occurred
in childhood or young adulthood of the offspring.
DISCUSSION
The present study is the first to examine cancer risks in early
adulthood of offspring born to one or two atomic bomb survivors
in Hiroshima and Nagasaki. Our results suggest that cancer
incidence in children and young adults did not increase relative to
parental exposure to atomic bombs. The estimates and 95%
confidence intervals of risk ratios provide an indication of the
magnitude of possible effects for all levels of preconception
exposure. For example, the 95% upper confidence bound of risk
ratios indicates that there might be a 34% increase in cancer
incidence rates among the subjects with two exposed parents
relative to the reference subjects. Our results are consistent with
those obtained in the latest study of cancer mortality in childhood
and young adulthood for the same cohort members (Izumi et al,
2003).
Our study is unique in certain respects. First, it involved a long-
term follow-up of a large fixed cohort of a single ethnic group;
second, the parents experienced single, whole-body exposures with
Table 2 Cancer incidence before and after 20 years of age among 40487 offspring of atomic-bomb survivors and controls
Age 1–19 years Age 20+ years
Cancer site ICD-9
a Male Female Male Female Total
Solid tumors 140–203, 225 15 9 234 317 575
Digestive 150–159 2 1 149 89 241
Respiratory 160–165 0 1 23 9 33
Female breast 174 0 0 0 88 88
Female genital organ 179–184 0 0 0 71 71
Male genital organ 185–187 1 0 14 0 15
Urinary 188–189 0 0 17 1 18
Brain and nervous 191,192,225 5 3 12 10 30
Thyroid 193 1 1 9 33 44
Other 6 3 10 16 35
Hematopoietic tumors 200–208 16 8 23 21 68
Leukemia 204–208 8 7 9 10 34
Lymphoma 200–202 8 1 14 11 34
aInternational Classification of Diseases, 9th Revision.
Table 3 Adjusted risk ratio for solid tumor before and after 20 years of age in the offspring, according to parental preconception exposure to atomic
bomb radiation
Age 1–19 years Age 20+ years
Dose (mSv) No. of cases
a Risk ratio 95% CI P-value
b No. of cases
a Risk ratio 95% CI P-value
b
Paternal exposure
0–4 (reference) 4 1.00 0.78 156 1.00 0.60
5–49 3 0.80 (0.17–3.68) 25 0.99 (0.63–1.49)
50–149 23 0.89 (0.55–1.35)
150–499 27 1.09 (0.71–1.63)
500–4000 16 0.68 (0.39–1.10)
Unknown 34 1.12 (0.76–1.61)
Continuous dose (100mSv)
1.03 (0.84–1.14) 0.66 0.96 (0.92–1.00) 0.07
Maternal exposure
0–4 (reference) 11 1.00 0.97 256 1.00 0.99
5–49 11 0.98 (0.42–2.31) 43 0.89 (0.63–1.23)
50–149 48 0.97 (0.70–1.31)
150–499 49 1.02 (0.74–1.38)
500–4000 34 1.02 (0.70–1.43)
Unknown 43 0.99 (0.70–1.36)
Continuous dose (100mSv) 1.02 (0.88–1.12) 0.73 1.01 (0.98–1.04) 0.53
aIn all, 55 offspring who developed solid cancer were conceived after both parents had been irradiated.
bTest for homogeneity of risk ratios among dose groups or test for trend
of linear dose response; baseline rates adjusted for city, sex, year of birth, residency, and age at entry.
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ya broad range of radiation dose and third, the reference group used
for the present analysis, in contrast to earlier studies of offspring of
survivors, included only subjects whose parents were in either city
of Hiroshima or Nagasaki at the time of the bombing and whose
radiation dose was 0–4mSv. The aim of these criteria was to
reduce the potential bias arising from unknown demographic
factors that might affect baseline cancer incidence. The atomic-
bomb survivor study has shown that dose-response analyses can
be biased if based on a comparison group that is not comparable to
the exposed subjects with respect to uncontrolled factors related to
disease mortality (Cologne and Preston, 2001).
The present analysis is limited by a lack of detailed information
on individual characteristics including socioeconomic, lifestyle,
and biological factors that could affect cancer risks, particularly in
early adult life. A mail survey of 24000 offspring, which was started
in 2001 and is to be completed in 2005, will provide information on
education, alcohol consumption, smoking behavior, dietary habits,
daily exercise, and morbidity. In 2002, RERF began a clinical
programme for the survey participants that collects information on
clinical and laboratory measurements; this will be incorporated in
future analyses of these offspring.
A strength is that population-based tumor registry data allowed
us to assess cancer risks more precisely than in previous cancer
mortality studies. This, essentially, is because improved cancer
therapy over the last few decades has decreased the fatality of some
cancers so that a number of nonfatal cancer cases did not appear
on death certificates. The proportion of cancer cases documented
by death certificates only was 2.8%. Misclassification of cancer on
death certificates may also have reduced the number of cancers.
Comparisons of certified causes of death and autopsy diagnoses
have shown that the percentage of cancer misclassification on
death certificates (i.e. true cancers misclassified as noncancer)
among atomic-bomb survivors was 10% for those aged under 65
years in the period 1961–1975 (Sposto et al, 1992). Histological
confirmation of tumor cases from tissue registries has improved
the quality of tumor registry data. Although tumors among the
subjects who moved away from Hiroshima or Nagasaki were not
included in the tumor registry data, the effects of migration on the
baseline cancer rates were adjusted using the residence probabil-
ities. The absence of cancer incidence data in the period 1946–
1957 does not materially affect our results because the mortality
data indicated that few offspring died from cancer during that
period.
A careful interpretation is necessary for the suggested trend of
decreasing adulthood cancer incidence for increasing paternal
dose. Adjusted risk ratio of cancer mortality at 100mSv was 0.95
(95% CI 0.87–1.01) for paternal exposure (Izumi et al, 2003),
which is consistent with the results of the present analysis. The
upper 95% confidence bound of adjusted risk ratio is slightly
above 1.0 for both cancer incidence and mortality. Because
residence probabilities were not affected by parental exposure to
atomic bombs (unpublished data), migration may not be a
plausible explanation for this finding. Thus, continuous follow-
up data are necessary to examine this temporal pattern.
Risk assessment of cancer at advanced ages among the cohort
members will require at least 30 more years of follow-up. In the
present study, 77% of the offspring had passed their 40th year, but
only 20% had reached 50 years of age. According to the National
Life Table (Japanese Ministry of Health, Labour and Welfare),
mean life expectancy (years) in Japan in 2001 was 78.07 for men
and 84.93 for women. Such long life expectancies should make it
possible to fully assess the effects of parental irradiation. Thus,
further follow-up studies of the offspring of atomic-bomb
survivors will help to address some of the limitations of our
present analysis.
We concluded that we can not yet exclude an increase in cancer
incidence among offspring of atomic bomb survivors, because of the
small number of cases and the relatively young age of study subjects.
However, our findings provide useful information of direct relevance
to current public concerns about the health of offspring whose
parents were exposed to ionizing radiation prior to conception,
whether from therapy, their occupation, or their houses.
Table 4 Adjusted risk ratio for hematopoietic tumor before and after 20 years of age in the offspring, according to parental preconception exposure to
radiation
Age 1–19 years Age 20+ years
Dose (mSv) No. of cases
a Risk ratio 95% CI P-value
b No. of cases
a Risk ratio 95% CI P-value
b
Paternal exposure
0–4 (reference) 7 1.00 0.47 11 1.00 0.86
5–49 7 1.07 (0.36–3.13) 3 1.68 (0.37–5.60)
50–149 1 0.58 (0.03–3.06)
150–499 2 1.10 (0.17–4.21)
500–4000 1 0.63 (0.03–3.28)
Unknown 0 Not estimated
Continuous dose (100mSv) 0.97 (0.73–1.09) 0.70 0.91 (0.65–1.07) 0.36
Maternal exposure
0–4 (reference) 7 1.00 0.14 23 1.00 0.90
5–49 10 1.55 (0.59–4.28) 4 0.96 (0.28–2.53)
50–149 3 0.66 (0.16–1.92)
150–499 6 1.40 (0.51–3.24)
500–4000 3 0.99 (0.23–2.87)
Unknown 3 0.72 (0.17–2.10)
Continuous dose (100mSv) 1.04 (0.89–1.13) 0.58 0.97 (0.83–1.07) 0.63
a6 offspring who developed hematopoietic tumor were conceived after both parents had been irradiated.
bTest for homogeneity of risk ratios among dose groups or test for
trend of linear dose response; baseline rates adjusted for city, sex, year of birth, residency, and age at entry.
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